Location History:
- Florence, IT (2004)
- Milan, IT (2010 - 2018)
Company Filing History:
4 out of 6 
3 out of 7 
1 out of 51 Years Active: 2004-2018
Title: Massimo Iacobelli: Innovator in Medical Formulations
Introduction
Massimo Iacobelli is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of medical formulations, particularly in the treatment and prophylaxis of graft versus host disease (GVHD). With a total of 8 patents to his name, Iacobelli's work has the potential to impact the lives of many patients undergoing hematopoietic stem cell transplantation.
Latest Patents
Iacobelli's latest patents include innovative formulations aimed at addressing GVHD. One notable patent is for the use of defibrotide in the prophylaxis and treatment of GVHD in humans, especially in the context of hematopoietic stem cell transplantation. This invention focuses on both acute and chronic forms of GVHD, with a preference for acute cases. Another significant patent involves a novel formulation designed to increase the number of stem cells and progenitor cells in circulation. This formulation combines defibrotide with at least one hematopoietic factor, such as G-CSF, to enhance the mobilization of hematopoietic progenitor cells.
Career Highlights
Throughout his career, Massimo Iacobelli has worked with notable companies in the medical field, including Gentium S.p.a. and Gentium S.r.l. His expertise and innovative approach have positioned him as a key figure in the development of medical treatments that address critical health challenges.
Collaborations
Iacobelli has collaborated with esteemed colleagues, including Laura Ferro and Roberto Porta. These partnerships have contributed to the advancement of his research and the successful development of his patented innovations.
Conclusion
Massimo Iacobelli's contributions to medical formulations and his innovative patents demonstrate his commitment to improving patient outcomes in the field of hematopoietic stem cell transplantation. His work continues to pave the way for advancements in the treatment of graft versus host disease.